Plant Name: Pogostemon cablin
Taxonomic Information:
Plant ID: NPO29463
Plant Latin Name: Pogostemon cablin
Taxonomy Genus: Pogostemon
Taxonomy Family: Lamiaceae
Plant External Links:
NCBI TaxonomyDB:
28511
Plant-of-the-World-Online:
454827-1
Used in Medicines:
Country/Region:
Malaysia; Indonesia; India; ChinaTraditional Medicine System:
Indian Folk; TCM; AyurvedaGeographical Distribution:
Australia; Trinidad and Tobago; Philippines; Indonesia; India; Malaysia; Vietnam; China; Sri Lanka; Thailand; Taiwan; Fiji
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; NPSR1; | |
| ADORA3; ADORA2A; ADORA1; FFAR1; FFAR4; | |
| CDC25B; | |
| ACHE; | |
| BLM; ADK; ALOX12; HSD17B1; AKR1B1; HSD17B2; HSD17B10; NOX4; ALOX15; ALDH1A1; POLB; | |
| AURKB; MET; AXL; FLT3; CDK1; PIM1; KDR; IGF1R; CDK8; CSNK2A1; | |
| CA2; CA12; CA14; CA7; CA4; | |
| PPARA; | |
| ESR2; | |
| THRB; | |
| NR1H4; | |
| TYR; | |
| MMP9; MMP1; MMP12; MMP2; | |
| AHR; HIF1A; TP53; NFKB1; | |
| ABCG2; | |
| LMNA; FABP3; FABP5; FABP4; THPO; | |
| SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
| Enzyme_unclassified | ADK | Adenosine kinase | P55263 | CHEMBL3589 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Metallo protease | MMP1 | Matrix metalloproteinase-1 | P03956 | CHEMBL332 |
| Metallo protease | MMP12 | Matrix metalloproteinase 12 | P39900 | CHEMBL4393 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Nuclear hormone receptor subfamily 1 group A | THRB | Thyroid hormone receptor beta-1 | P10828 | CHEMBL1947 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
| Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
| Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
| Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
| Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
| Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
| Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
| Protein Kinase | CDK8 | Cell division protein kinase 8 | P49336 | CHEMBL5719 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| Protein Phosphatase | CDC25B | Dual specificity phosphatase Cdc25B | P30305 | CHEMBL4804 |
| Small molecule receptor (family A GPCR) | ADORA3 | Adenosine A3 receptor | P0DMS8 | CHEMBL256 |
| Small molecule receptor (family A GPCR) | ADORA2A | Adenosine A2a receptor | P29274 | CHEMBL251 |
| Small molecule receptor (family A GPCR) | ADORA1 | Adenosine A1 receptor | P30542 | CHEMBL226 |
| Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
| Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
| Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
| Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
| Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.021E-10 | 1.389E-07 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP3A4, NOX4 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 8.465E-10 | 8.015E-07 | CA12, CA14, CA2, CA4, CA7 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 9.301E-09 | 5.330E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.991E-08 | 1.032E-05 | CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 4.301E-08 | 1.911E-05 | ALOX12, ALOX15, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0050728; negative regulation of inflammatory response | 8.276E-08 | 3.337E-05 | ADORA1, ADORA2A, CYP19A1, FFAR4, NFKB1, NR1H4, PPARA |
| BP | GO:0008283; cell proliferation | GO:0008284; positive regulation of cell proliferation | 9.310E-08 | 3.620E-05 | AKR1B1, ALOX12, CDC25B, CDK1, CSNK2A1, FLT3, HIF1A, IGF1R, KDR, MMP12, MMP2, MMP9, PIM1, THPO, TSHR |
| MF | GO:0005488; binding | GO:0020037; heme binding | 1.728E-07 | 5.974E-05 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP3A4, NOX4 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 2.171E-07 | 7.061E-05 | BLM, CA12, CA2, CA4, CA7, ESR2, MMP1, MMP12, MMP2, MMP9, NR1H4, PPARA, THRB, TP53 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 2.851E-07 | 8.302E-05 | CA12, CA14, CA2, CA4, CA7 |
| BP | GO:0050896; response to stimulus | GO:0033993; response to lipid | 3.822E-07 | 1.053E-04 | AXL, CA2, CSNK2A1, CYP1A1, CYP1A2, FABP3, FFAR1, FLT3, HSD17B2, NFKB1, NR1H4, TP53, TYR |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 5.527E-07 | 1.352E-04 | CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 6.255E-07 | 1.488E-04 | CYP1A2, CYP2C19, CYP3A4 |
| MF | GO:0060089; molecular transducer activity | GO:0001609; G-protein coupled adenosine receptor activity | 1.092E-06 | 2.265E-04 | ADORA1, ADORA2A, ADORA3 |
| MF | GO:0005488; binding | GO:0005504; fatty acid binding | 1.598E-06 | 3.134E-04 | FABP3, FABP4, FABP5, FFAR4 |
| BP | GO:0050896; response to stimulus | GO:0009611; response to wounding | 1.670E-06 | 3.218E-04 | ACHE, ADORA3, ALOX15, CDK1, CYP1A1, PPARA, TP53 |
| BP | GO:0050896; response to stimulus | GO:0001666; response to hypoxia | 1.696E-06 | 3.236E-04 | ADORA1, CYP1A1, HIF1A, LMNA, MMP2, NOX4, PPARA, TP53 |
| BP | GO:0009987; cellular process | GO:0001973; adenosine receptor signaling pathway | 2.609E-06 | 4.657E-04 | ADORA1, ADORA2A, ADORA3 |
| MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 3.234E-06 | 5.376E-04 | AHR, CSNK2A1, HIF1A, KDR |
| MF | Unclassified; | GO:0004872; receptor activity | 5.149E-06 | 7.787E-04 | ADORA1, ADORA2A, ADORA3, AHR, AXL, ESR2, FFAR1, FFAR4, FLT3, IGF1R, KDR, MET, NPSR1, NR1H4, PPARA, THRB, TSHR |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 5.247E-06 | 7.880E-04 | CA12, CA2, CA4, CA7 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 6.787E-06 | 9.893E-04 | CYP1A2, CYP2C19, CYP3A4 |
| MF | GO:0005488; binding | GO:0042562; hormone binding | 7.784E-06 | 1.116E-03 | ACHE, ALDH1A1, HSD17B1, IGF1R, THRB |
| BP | Unclassified; | GO:0044259; multicellular organismal macromolecule metabolic process | 8.244E-06 | 1.173E-03 | HIF1A, MMP1, MMP12, MMP2, MMP9 |
| BP | GO:0008152; metabolic process | GO:0006703; estrogen biosynthetic process | 8.802E-06 | 1.221E-03 | CYP19A1, HSD17B1, HSD17B2 |
| BP | GO:0023052; signaling | GO:0032230; positive regulation of synaptic transmission, GABAergic | 8.802E-06 | 1.221E-03 | ADORA2A, CA2, CA7 |
| BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 1.014E-05 | 1.338E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 1.014E-05 | 1.338E-03 | ALOX12, ALOX15 |
| BP | GO:0008152; metabolic process | GO:0006367; transcription initiation from RNA polymerase II promoter | 1.232E-05 | 1.588E-03 | CDK1, CDK8, ESR2, NR1H4, PPARA, THRB |
| BP | GO:0008152; metabolic process | GO:0010557; positive regulation of macromolecule biosynthetic process | 1.278E-05 | 1.636E-03 | AHR, AURKB, BLM, CDK1, CDK8, ESR2, HIF1A, IGF1R, KDR, MET, MMP12, NFKB1, NOX4, NR1H4, PPARA, THRB, TP53 |
| BP | GO:0009987; cellular process | GO:0030522; intracellular receptor signaling pathway | 2.049E-05 | 2.432E-03 | AHR, ESR2, NR1H4, PIM1, PPARA, THRB |
| BP | Unclassified; | GO:0044236; multicellular organism metabolic process | 2.284E-05 | 2.660E-03 | HIF1A, MMP1, MMP12, MMP2, MMP9 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 3.035E-05 | 3.271E-03 | CA2, CA7 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 3.035E-05 | 3.271E-03 | CYP1A1, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 3.035E-05 | 3.271E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 3.035E-05 | 3.271E-03 | ALOX12, ALOX15 |
| CC | GO:0044464; cell part | GO:0099056; integral component of presynaptic membrane | 3.035E-05 | 3.271E-03 | ADORA1, ADORA2A |
| MF | GO:0060089; molecular transducer activity | GO:0003707; steroid hormone receptor activity | 3.837E-05 | 4.017E-03 | ESR2, NR1H4, PPARA, THRB |
| BP | GO:0008152; metabolic process | GO:0046777; protein autophosphorylation | 3.875E-05 | 4.038E-03 | AURKB, CSNK2A1, FLT3, IGF1R, KDR, PIM1 |
| MF | GO:0005488; binding | GO:0042802; identical protein binding | 3.991E-05 | 4.138E-03 | ABCG2, ACHE, ADORA2A, BLM, CSNK2A1, ESR2, FLT3, IGF1R, KDR, MET, MMP9, NFKB1, SMN1, SMN2, TP53, TYR |
| BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 4.019E-05 | 4.148E-03 | CYP1A1, POLB, TP53 |
| BP | GO:0051179; localization | GO:0006909; phagocytosis | 4.101E-05 | 4.178E-03 | ADORA1, ADORA2A, ALOX15, AXL |
| BP | GO:0009987; cellular process | GO:0070301; cellular response to hydrogen peroxide | 4.378E-05 | 4.414E-03 | AKR1B1, AXL, CDK1, CYP1B1 |
| BP | GO:0050896; response to stimulus | GO:0009725; response to hormone | 4.378E-05 | 4.414E-03 | AKR1B1, CA2, CSNK2A1, CYP1A2, FABP3, FFAR4, FLT3, NFKB1, PPARA, TSHR |
| BP | GO:0023052; signaling | GO:0046887; positive regulation of hormone secretion | 5.045E-05 | 4.971E-03 | ADORA2A, CYP19A1, FFAR1, HIF1A, NR1H4 |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 5.327E-05 | 5.179E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 5.397E-05 | 5.223E-03 | ADORA1, ADORA2A, CA2, CA7, KDR, NPSR1 |
| BP | GO:0008152; metabolic process | GO:0030574; collagen catabolic process | 5.626E-05 | 5.397E-03 | MMP1, MMP12, MMP2, MMP9 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 6.057E-05 | 5.701E-03 | CYP1A1, CYP1A2 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 6.057E-05 | 5.701E-03 | CYP1A2, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 6.887E-05 | 6.328E-03 | FABP3, FABP4, FABP5 |
| BP | GO:0008152; metabolic process | GO:0006706; steroid catabolic process | 7.767E-05 | 7.080E-03 | CYP19A1, CYP1A2, CYP3A4 |
| BP | GO:0032502; developmental process | GO:0007568; aging | 9.634E-05 | 8.459E-03 | AURKB, CDK1, CYP1A1, NOX4, POLB, TP53 |
| BP | GO:0008152; metabolic process | GO:0051122; hepoxilin biosynthetic process | 1.007E-04 | 8.671E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 1.007E-04 | 8.671E-03 | CYP1A1, CYP3A4 |
| BP | GO:0032502; developmental process | GO:0031100; animal organ regeneration | 1.038E-04 | 8.832E-03 | AXL, CDK1, CSNK2A1, FLT3 |
| BP | GO:0009987; cellular process | GO:0050714; positive regulation of protein secretion | 1.059E-04 | 8.969E-03 | ACHE, ADORA2A, FFAR1, HIF1A, MMP12, NR1H4 |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 5.154E-10 | 7.680E-08 | HSD17B1, CYP1A2, HSD17B2, CYP1A1, CYP1B1, CYP3A4, CYP19A1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 9.894E-09 | 4.914E-07 | HSD17B1, HSD17B2, CYP1A1, CYP1B1, CYP19A1, IGF1R |
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 1.460E-09 | 1.088E-07 | CA12, CA2, CA4, CA7, CA14 |
| 09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 3.500E-06 | 7.450E-05 | FLT3, MMP1, MMP2, HIF1A, MET, TP53, MMP9, NFKB1, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 3.068E-06 | 7.450E-05 | MMP2, KDR, TP53, HIF1A, MMP9, MET, IGF1R |
| 09150 Organismal Systems | 09152 Endocrine system | hsa03320 | PPAR signaling pathway | 2.344E-06 | 6.984E-05 | FABP3, FABP4, FABP5, MMP1, PPARA |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 1.876E-06 | 6.984E-05 | CYP1A2, ALOX15, CYP3A4, CYP2C19 |
| Unclassified | Unclassified | hsa01100 | Metabolic pathways | 2.003E-05 | 2.713E-04 | ALOX15, ADK, AKR1B1, ALOX12, CYP2C19, CYP3A4, TYR, CYP19A1, HSD17B10, HSD17B1, HSD17B2, CYP1A2, ALDH1A1, CYP1A1 |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 5.517E-06 | 1.028E-04 | CYP1A2, CYP1A1, CYP1B1, CYP3A4, CYP2C19 |
| 09160 Human Diseases | 09161 Cancers | hsa05219 | Bladder cancer | 7.779E-06 | 1.288E-04 | MMP1, MMP2, MMP9, TP53 |
| 09160 Human Diseases | 09161 Cancers | hsa05206 | MicroRNAs in cancer | 3.628E-05 | 4.505E-04 | PIM1, CYP1B1, TP53, MMP9, MET, NFKB1, CDC25B |
| 09160 Human Diseases | 09161 Cancers | hsa05202 | Transcriptional misregulation in cancer | 1.979E-05 | 2.713E-04 | FLT3, TP53, MMP9, MET, NFKB1, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 5.544E-05 | 5.900E-04 | FLT3, TP53, MET, HIF1A |
| 09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 4.919E-05 | 5.638E-04 | CYP1A2, ALDH1A1, CYP1A1, CYP3A4 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 7.763E-05 | 7.230E-04 | CYP1A2, CYP1A1, CYP1B1, CYP3A4 |
| 09150 Organismal Systems | 09154 Digestive system | hsa04976 | Bile secretion | 6.963E-05 | 6.916E-04 | CA2, NR1H4, CYP3A4, ABCG2 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04024 | cAMP signaling pathway | 3.789E-04 | 3.136E-03 | ADORA2A, ADORA1, PPARA, NFKB1, TSHR |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04071 | Sphingolipid signaling pathway | 5.256E-04 | 4.122E-03 | ADORA3, ADORA1, TP53, NFKB1 |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 2.583E-04 | 2.264E-03 | CYP1A2, CYP1A1, CYP1B1 |
| 09160 Human Diseases | 09161 Cancers | hsa05221 | Acute myeloid leukemia | 7.368E-04 | 5.227E-03 | FLT3, PIM1, NFKB1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04923 | Regulation of lipolysis in adipocytes | 6.995E-04 | 5.211E-03 | FABP4, ADORA1, TSHR |
| 09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04080 | Neuroactive ligand-receptor interaction | 1.670E-03 | 9.573E-03 | THRB, ADORA2A, ADORA3, ADORA1, TSHR |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00590 | Arachidonic acid metabolism | 9.419E-04 | 6.379E-03 | ALOX15, ALOX12, CYP2C19 |
| 09160 Human Diseases | 09161 Cancers | hsa05218 | Melanoma | 1.395E-03 | 8.664E-03 | TP53, MET, IGF1R |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 1.285E-03 | 8.324E-03 | CYP1A2, CYP3A4, CYP2C19 |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04520 | Adherens junction | 1.572E-03 | 9.371E-03 | CSNK2A1, MET, IGF1R |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| C00-D49: Neoplasms | Cancer | C00-C96 | PIM1; MET; CDK1; IGF1R; KDR; CSNK2A1; NFKB1; FLT3; ACHE; HIF1A; ADORA3; MMP9; TP53; MMP2; CDC25B; |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MET; AURKB; IGF1R; KDR; FLT3; HIF1A; MMP9; TP53; MMP2; |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2; |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; |
| I00-I99: Diseases of the circulatory system | Cardiac disease | I00-I99 | ADORA1; |
| I00-I99: Diseases of the circulatory system | Cardiac arrhythmias | I47-I49 | ADORA1; |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | ADORA1; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Convulsions | R56.0 | ADK; |
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; |
| C00-D49: Neoplasms | Gastric cancer | C16 | KDR; |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | ADORA3; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | AKR1B1; MMP1; TYR; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Fatigue | R53 | ADORA1; |
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Atrial fibrillation | E78, I48 | ADORA1; |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53; |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
| K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ADORA1; THRB; |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MMP12; ADORA2A; |
| C00-D49: Neoplasms | Glioma | C71 | KDR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; ADORA1; |
| C00-D49: Neoplasms | CLL | NA | FLT3; |
| NA: NA | Edema | NA | CA2; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | IGF1R; KDR; FLT3; MMP9; TP53; |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3; |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | ADORA3; |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; |
| G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R; |
| C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; AHR; |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ADORA1; |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypothyroidism | E03 | THRB; |
| I00-I99: Diseases of the circulatory system | Coronary disorder diagnosis | I20-I25 | ADORA2A; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ADORA1; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | CDK1; IGF1R; ACHE; ADORA2A; ADK; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKB; FLT3; TP53; |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; TSHR; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | MMP1; |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | ADORA2A; |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
| C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET; |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; ADK; |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | ADK; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | MMP12; ADORA1; ADORA2A; |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | MMP12; |
| H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |
| C00-D49: Neoplasms | Melanoma | C43 | KDR; TYR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR; |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; AKR1B1; TP53; |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53; |
| I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET; |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Radionuclide imaging | W88 | ADORA2A; |
| C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R; |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; ACHE; CA2; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2; |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A; |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; ADORA1; ADORA2A; ADORA3; AKR1B1; |
| NA: NA | GIST | NA | FLT3; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | ADORA2A; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | MMP1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | MMP2; |
| I00-I99: Diseases of the circulatory system | Orthostatic hypotension | I95.1 | ADORA1; |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53; |
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; |
| C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Lipid metabolism disorder | E75-E78 | THRB; |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Wound healing | T14.0-T14.1 | THRB; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1; |
| C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; MMP2; |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | ADORA3; |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADORA1; ADORA2A; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypertriglyceridemia | E78.1, E78.2, E78.3, I47-I49 | ADORA1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperthyroidism | E05 | THRB; |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; ADORA1; ADORA2A; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | KDR; FLT3; MMP2; |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ADORA3; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MMP12; |
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9; |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | AURKB; TP53; |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
| NA: NA | Hepatitis C virus infection | NA | ADORA3; |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR; ADORA3; |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
| I00-I99: Diseases of the circulatory system | Acute and chronic heart failure | I50 | ADORA1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | MMP2; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | High cholesterol levels in blood | E78.0 | THRB; |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1; |
| NA: NA | HIV infections | NA | AHR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | TYR; |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1; |
| C00-D49: Neoplasms | Prostate cancer | C61 | FLT3; |
| I00-I99: Diseases of the circulatory system | Aortic aneurysm | I71 | MMP12; |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; ACHE; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | ADORA1; AKR1B1; FFAR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; FFAR1; |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53; |
| N00-N99: Diseases of the genitourinary system | Renal failure | N17, N18, N19 | ADORA1; |
| C00-D49: Neoplasms | Renal cancer | C64 | KDR; |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; MMP2; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | NPSR1; |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | ADORA1; ADORA2A; |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; |
| NA: NA | Upper abdominal bloating | NA | ACHE; |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | FFAR1; |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; KDR; AXL; |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ADORA2A; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | ADORA1; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; |
| C00-D49: Neoplasms | AML | NA | KDR; FLT3; |
| C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1; |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
| C00-D49: Neoplasms | Metastasis | C00-C97 | AXL; |
| A00-B99: Certain infectious and parasitic diseases | Sepsis | A40, A41 | ADORA1; |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
| C00-D49: Neoplasms | Breast cancer | C50 | CDK1; IGF1R; KDR; FLT3; CYP19A1; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
